Markets

The Power of an Idea

I'd never heard of Noven, but it has the earmarks of a superior investment.

Doggone, Andrew Tanzer was right! Andrew is my colleague who came back from the Value Investing Congress in New York City a year ago and remarked that each time a presenter talked fervently about a stock, you could see attendees hunched over their BlackBerries, buying shares.

At the most recent such event I noticed the same phenomenon. At 9:40 a.m., when Lance Helfert, of West Coast Asset Management, began explaining the virtues of Noven Pharmaceuticals, its price stood at $14.86 a share. Scarcely an hour later, it was at $16.21. The power of a good idea is amazing, isn't it?

Good patchwork

I'd never heard of Noven (symbol NOVN), but it has many earmarks of a superior investment. It's a specialty-drug company whose forte is patches that adhere to the body and deliver medication. To borrow Helfert's phrase, this is "a beautiful business." Patches work with many compounds. Because a patch can extend the life of a drug and differentiate it from similar drugs, big drug companies partnering with Noven pay its development-and-marketing costs. And Noven's unique technology, patented until 2014, allows it to pack doses of drugs into far smaller patches than those of its competitors.

Noven's biggest product is Vivelle-Dot, a patch that delivers estrogen to menopausal women. In a $1.7-billion market, Vivelle-Dot has a small but growing share and, says Helfert, "we believe it is the best product." Vivelle-Dot is a partnership with drug giant Novartis, and in 2007 Noven's after-tax share of the profit was expected to be roughly $35 million. If you multiply that by ten, says Helfert, the business value of this one product is $350 million, or $14 per share.

He ascribes another $85 million in value to a second patch, Daytrana, which is used to treat attention-deficit hyperactivity disorder in children and is sold in partnership with Shire Pharmaceuticals. The two companies hope to launch a second ADHD patch in 2010 to deliver amphetamine.

Beyond all that, Noven is involved in multiple partnerships for drug products in development that it will not disclose for competitive reasons. The company believes its patches can deliver 35 compounds treating everything from pain and depression to obesity and motion sickness.

I'd expect shares of a company with these attributes to be priced at least in the mid $20s. And, in fact, Noven Pharma was in the $25 range until it announced last July the purchase of privately owned JDS Pharmaceuticals for $125 million in cash -- yup, Noven is flush with money. The deal gave Noven two non-patch drugs belonging to JDS (and numerous others in the pipeline), as well as its own sales force. For whatever reason -- maybe investors were spooked because Noven moved away from total reliance on patch-delivered drugs -- the stock slid steadily down to the $14 range, where it stood when those BlackBerries started to deliver buy orders.

Moments of truth

I'm telling you all this because, frankly, I get a rush from good investment ideas. I'll never forget the day in 2004 that I interviewed Matt Rose, head of Burlington Northern Santa Fe, and realized midway through that the railroad business had fundamentally changed for the better -- and that almost nobody knew it. I can't count the number of times this magazine has since recommended BNSF stock.

So kudos to my fellow attendees of the Value Investing Congress for being alert. And here's to your own investment success in 2008.

Most Popular

13 States That Tax Social Security Benefits
social security

13 States That Tax Social Security Benefits

You may have dreamed of a tax-free retirement, but if you live in these 13 states, your Social Security benefits are subject to a state tax. That's on…
October 21, 2020
How to Be Happy (Not Bored!) in Retirement – Starting Today
happy retirement

How to Be Happy (Not Bored!) in Retirement – Starting Today

Here are 12 ways to prepare now for retirement so that you’ll be happy, active, fulfilled and never, ever bored.
October 21, 2020
Election 2020: Joe Biden's Tax Plans
taxes

Election 2020: Joe Biden's Tax Plans

With the economy still in trouble, tax policy takes on added importance in the 2020 election. So, let's take a look at what Joe Biden wants to do abou…
October 22, 2020

Recommended

Stock Market Today 10/22/20: Stimulus' Siren Song Pulls the Bulls Along
stocks

Stock Market Today 10/22/20: Stimulus' Siren Song Pulls the Bulls Along

Thursday's gains were driven by more positive language on stimulus negotiations, but an uncertain timeline kept those advances modest.
October 22, 2020
Where Millionaires Live in America
investing

Where Millionaires Live in America

Looking to rub elbows with the rich? These 15 metro areas have the highest concentrations of households with at least a million dollars in liquid asse…
October 22, 2020
Stock Market Today 10/21/20: Snap Soars, Netflix Nosedives as Stocks Sit and Wait
stocks

Stock Market Today 10/21/20: Snap Soars, Netflix Nosedives as Stocks Sit and Wait

Stocks mostly treaded water Wednesday as stimulus negotiations continued, but Snap (SNAP) and Netflix (NFLX) provided some fireworks.
October 21, 2020
Stock Market Today 10/20/20: Glimmer of Stimulus Hope Gives Stocks a Small Lift
stocks

Stock Market Today 10/20/20: Glimmer of Stimulus Hope Gives Stocks a Small Lift

Tuesday's rigid stimulus deadline seemingly blurred as House Democrats and the White House made progress toward a middle ground.
October 20, 2020